The results were in accordance with the preclinical study of DS-8273a, a humanized DR5 agonistic antibody newly generated by Sankyo [28,29], who suggested that TR2-3 is a potent antitumor agent for cancer therapy. Here, TNFRSF10B is linked to cancer.